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Outcomes are poor for patients with hematologic malignancies who experience overt relapse after allogeneic
hematopoietic stem cell transplantation (HCT). Data on outcomes of post-transplantation minimal residual
disease (MRD) are limited. In this single-institution, retrospective cohort analysis of children with acute
leukemia and myelodysplastic syndrome, we document the pattern of relapse with a primary focus on
outcomes of post-transplantation MRD. Forty of 93 patients (43%) who underwent a ﬁrst allogeneic HCT and
had systematic pretransplantation and post-transplantation MRD evaluations at þ30, þ60, þ90, þ180 days
and þ1 and þ2 years post-transplantation experienced relapse. The median time to relapse was 4.8 months
post-transplantation, with a median survival of 4 months post-relapse. Despite frequent, systematic, routine
post-HCT disease restaging evaluation, 31 patients (78%) presented with overt disease at the time of relapse.
Seven patients with acute leukemia who had post-transplantation MRD presented at a median of 1 month
post-transplantation. Owing to rapid disease progression or treatment-related mortality, there was no
improvement in survival in those patients whose leukemia was detected in a state of MRD post-
transplantation. Our results suggest that early intervention strategies targeting post-transplantation MRD
for relapse prevention in acute leukemia may not be feasible.
Published by Elsevier Inc. on behalf of American Society for Blood and Marrow Transplantation.INTRODUCTION setting of mixed chimerism has shown promise in relapse
Relapse is the primary cause of treatment failure in
patients with hematologic malignancies who undergo allo-
geneic hematopoietic stem cell transplantation (HCT) [1].
Once patients have relapsed after HCT, treatment options are
limited, and the outlook is generally poor [2-7]. One potential
approach to improving post-transplantation outcomes
involves preemptive interventions for relapse prevention.
Treatment of post-transplantation minimal residual disease
(MRD; deﬁned as <5% bone marrow blasts or positive cyto-
genetic or molecular markers of disease) to prevent overt
relapse may be one such strategy [8,9].
The majority of previous studies evaluating post-
transplantation relapse in acute leukemia are based on
patients presenting with overt morphological relapse or
high disease burden, in whom outcomes are poor [3,4,6].
However, with frequent post-transplantation surveillance
and more sensitive measures of detection, in theory dis-
ease recurrence could be detected both earlier and at a
state of lower disease burden that may be more amenable
to treatment, potentially leading to improved outcomes
[10-12]. Certainly, preemptive immunotherapy in theedgments on page 1006.
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donor lymphocyte infusion (DLI) in the setting of chronic
myelogenous leukemia (CML) before hematologic relapse
has lead to durable remissions [17-19]. Outcomes with DLI
for treatment of acute leukemia are quite variable, how-
ever [20-22]. Data on the outcomes of post-transplantation
MRD speciﬁcally in the setting of acute leukemia are
limited [21,23-26].
In this study, we describe the presentation and man-
agement of children with hematologic malignancies who
experience post-transplantation relapse. With a focus on
understanding the pattern of relapse, the goal was to
determine whether post-transplantation MRD is amenable
to intervention for relapse prevention.METHODS
Patients and Inclusion Criteria
This was a single-institution, retrospective cohort study of pediatric
patients (age 21 years) who relapsed after having undergone a ﬁrst allo-
geneic HCT for a hematologic malignancy between January 1, 2003, and
December 31, 2010, at The Johns Hopkins Hospital. This cohort included all
patients with a diagnosis of acute lymphoblastic leukemia (ALL), acute
myelogenous leukemia (AML), myelodysplastic syndrome (MDS), mixed
phenotypic acute leukemia (MPAL), or lymphoblastic lymphoma (LBL)
irrespective of disease status, pretransplantation conditioning, donor and
stem cell source, HLA matching, or any other transplant-related variables.
Patients with other types of leukemia, including blast crisis CML, were
excluded. For this analysis, 1 patient with LBL was analyzed with the pa-
tients with ALL. This study was approved by The Johns Hopkins Hospital’s
Institutional Review Board.Society for Blood and Marrow Transplantation.
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All patients underwent pretransplantation disease evaluation. Routine
post-transplantation surveillance was performed at 30, 60, 90, and 180 days
 10 days and 1 year and 2 years  1 month post-transplantation and as
clinically indicated thereafter. Evaluation was disease-speciﬁc and included
evaluation of chimerism (peripheral blood and bone marrow) and ﬂow
cytometry, cytogenetic, and molecular MRD studies (eg, bcr/abl in Phila-
delphia chromosomeepositive ALL) from the bone marrow. In addition,
lumbar punctures were routinely performed at the foregoing time points to
assess central nervous system (CNS) status in all patients.
The day of relapse after HCT was deﬁned as the ﬁrst day of laboratory
conﬁrmation of disease presence, inclusive of post-transplantation MRD. In
patients with ALL, MRD was assessed in our central reference laboratory
using ﬂow cytometry methods as described previously [27]. Following
deﬁnitions published by Leung et al. [28], MRD was positive at a level
0.01%. For AML, the sensitivity for routine ﬂow cytometry analysis ranged
from approximately 0.1% to 1% of cells, depending on the phenotype of the
initial leukemia. Treatment-related mortality (TRM) was deﬁned as death
unrelated to progressive disease and included transplantation-related
mortality or death due to treatment of post-transplantation relapse.
Statistical Analysis
The primary endpoint was overall survival after post-transplantation
relapse. Overall survival was deﬁned by the date of relapse until the date
of death, censored at the last follow-up date for patients who were alive at
the time of this analysis. Probabilities of survival were evaluated using the
Kaplan-Meier method. The cumulative incidence of relapse, adjusted for the
competing risk of death from TRM, was calculated using the method of
Gooley et al. [29]. The t test for numerical variables and Fisher’s exact test for
categorical variables were used to test for differences in characteristics be-
tween patients who relapsed and those who did not relapse. Analysis of
variance was used to analyze the differences among the various pre-
sentations of post-transplantation relapse, speciﬁcally by the time to
relapse. The level of statistical signiﬁcance was set at P < .05. Statistical
analyses were performed with Stata/IC version 12.0 (StataCorp, College
Station, TX).
RESULTS
Patient and Relapse Characteristics
Forty of 93 pediatric patients (43%) who underwent a ﬁrst
allogeneic HCT for acute leukemia orMDS relapsed after HCT.
Patient characteristics are summarized in Table 1. This
number included 21 relapses among 57 patients (37%) with
ALL or AML who were in morphological remission and
underwent a myeloablative transplantation (Table 2). The
cumulative incidence of post-HCT relapse, accounting for the
competing risk of transplantation-related mortality, was 17%
at 3 months, 26% at 6 months, 37% at 12 months, and 41% at
24 months (Figure 1). This included 41 patients with AML
(18 of whom relapsed), 34 with ALL (16 of whom relapsed),
10 with MPAL (4 of whom relapsed), and 8 with MDS (2 of
whom relapsed).
At the time of relapse, the majority of patients (n ¼ 31;
78%) presented with morphological (>5% disease) relapse.
Twenty-two patients (56%) had clinical signs and symptoms
consistent with relapse, including presentation with peri-
pheral blasts, extramedullary disease, cytopenias prompting
disease evaluation, and/or other symptoms concerning for
disease recurrence (eg, pain). Speciﬁcally, 3 patients had
leukemia cutis or chloromatous masses, and 1 patient pre-
sented with a testicular mass that prompted further evalu-
ation. Eight patients (21%) were asymptomatic, with relapse
discovered at prespeciﬁed routine disease evaluations,
including 2 patients with isolated CNS relapse. Nine patients
(23%) presented with post-transplantation MRD that was
detected on routine surveillance, including 7 patients with
leukemia and 2withMDS. Details regarding the presentation
of relapse were not available for 1 patient with conﬁrmed
morphological relapse.
The median time to relapse for all patients was 4.8
months (range, 0.1 to 57months) post-transplantation. Therewas a statistically signiﬁcant difference in the time to relapse
by presentation; patients with MRD-positive relapse (n ¼ 9)
presented at a median of 1 month post-HCT, those with
evidence of disease detected by routine surveillance (n ¼ 8)
presented at amedian of 3months post-HCT plant, and those
with overt relapse (n ¼ 22) presented at a median of 7.5
months post-HCT (P < .001) (Figure 2). After patients with
refractory disease were excluded, the median time to relapse
for patients with AML and ALL was 4.5 months (range, 1 to
15.8 months) for patients with AML (n ¼ 12) and 6 months
(range, 1 to 29 months) for those with ALL (n ¼ 14).
Management of Relapse
Decisions regarding the treatment of relapse varied and
were based on the timing of relapse, the patient’s condition,
and physician and patient/family preference. Six patients
received only supportive care, including hospice, palliative,
or complementary medicine. In 3 patients, immunosup-
pressive therapy was withdrawn in response to MRD
detection. Twenty-four patients received cytotoxic and/or
radiation therapy, and 13 received DLI (with or without
previous chemotherapy). Eleven patients were able to pro-
ceed to a second allogeneic HCT after attaining remission.
Overall Survival after Post-Transplantation Relapse and
Nonrelapse Mortality
Overall survival (OS) was 30% at 6 months, 17.5% at 1 year,
15% at 2 years, and 11% at 5 years post-relapse. Median sur-
vival after relapse was 4 months (range, 0.1 to 33 months).
Five of 40 patients (12.5%) are currently alive at a median
follow-up of 39months, including 2 patientswho continue to
be treated for active disease. One survivor had MDS and pre-
sented withMRD alone; the remaining 4 survivors presented
with overt disease, including 3 with ALL and 1 with MPAL.
Death post-relapse was due to a various causes. The
majority of patients died with progressive disease (n ¼ 28).
None of the 18 patients with AML survived after post-
transplantation relapse. Survival did not appear to differ
by therapeutic approach to relapse, with the exception of
those who underwent a second HCT. The 3-year overall
survival probability among the 11 patients who underwent
a second transplant was 27% (95% conﬁdence interval [CI],
6.5% to 54%), compared with 5.4% (95% CI, 0 to 20%) for
those who did not (P ¼ .02). The patients who proceeded to
a second transplantation more often had a later relapse
(median time to relapse, 8 months [range, 1 to 29 months])
than those who did not undergo a second transplantation
(median time to relapse, 3.8 months [range, 1 to 58
months]). Eight patients died from TRM related to the sec-
ond transplantation, including 3 patients who developed
grade IV acute graft-versus-host disease (GVHD). Three
patients remain long-term survivors following second
transplantation.
Outcomes of Post-Transplantation MRD
All 9 patients who presented with post-transplantation
MRD were discovered on routine planned surveillance.
These patients presented at a median of 1-month post-
transplantation (range, 1 to 6 months), with 8 exhibiting
some evidence of pretransplantation disease. Among the
7 patients with leukemia, 5 had very rapid progression of
disease to overt relapse, at a median of 21 days (range, 13 to
24 days) from detection of MRD despite intervention in
response to MRD, including early withdrawal of immuno-
suppression (n ¼ 3) and DLI (n ¼ 2) (Table 3). All patients
Table 1
Characteristics of Pediatric Patients Undergoing First Allogeneic HCT for Acute Leukemia Compared with the Subset Who Relapsed after HCT
Variable All Patients (n ¼ 93), n (%) Patients Who Relapsed Post-HCT (n ¼ 40), n (% of All Patients) P Value*
Median age at HCT, years (range) 10 (0.6-21.2) 9 (0.7-20.2) NS
Male sex 62 (67) 29 (47) NS
Diagnosis
AML 41 (44) 18 (44) NS
ALL 34 (37) 16 (47)
MPAL 10 (11) 4 (40)
MDS 8 (9) 2 (25)
Disease status at HCT, by disease
AML
Active disease 8 (9) 5 (63)x <.01y
MRD þ CR 13 (14) 6 (46)
MRD Neg CR 20 (22) 7 (35)
ALL
Active disease 1 (8) 1 (100)
MRD þ CR 13 (14) 8 (62)
MRD Neg CR 20 (22) 7 (35)
MPAL
Active disease 1 (8) 1 (100)
MRD þ CR 1 (8) 0 (0)
MRD Neg CR 8 (9) 3 (38)
MDS 8 (9) 2 (25)
Performance Status at HCT
80-100% 84 (90) 33 (39) .02
40-70% 8 (9) 6 (75)
Indication for HCT (for leukemia patients only; n ¼ 85)
Primary induction failure 12 (13) 6 (50) NS
High-risk diseasez 24 (26) 6 (25)
Relapsed disease 25 (27) 10 (40)
Multiple indications 24 (26) 16 (67)
Remissions (for leukemia patients only, n ¼ 85)
CR1 41 (44) 16 (39) NS
CR2 27 (63) 12 (44)
CR3þ 7 (9) 4 (57)
Refractory 10 (11) 7 (70)x
HCT conditioning regimen
Myeloablative 79 (85) 30 (38) <.01
Reduced intensity 14 (15) 10 (71)
Stem cell source
Bone marrow 71 (76) 34 (48) NS
Single cord blood 18 (19) 6 (33)
Double cord blood 1 (1) 0 (0)
Peripheral blood 3 (3) 0 (0)
Donor type
Matched sibling 26 (28) 11 (42) NS
Matched unrelated 30 (32) 12 (40)
Cord blood 19 (20) 6 (32)
Haploidenticalk 15 (16) 9 (60)
Mismatched related/unrelated 3 (3) 2 (67)
HCT indicates hematopoietic stem cell transplantation; AML, acute myelogenous leukemia; ALL, acute lymphoblastic leukemia; MPAL, mixed phenotypic acute
leukemia; MDS, myelodysplastic syndrome; MRD, minimal residual disease; CR, complete remission; NS, not signiﬁcant.
Active disease deﬁned by>5% blasts, including those with refractory disease. MRD includes patients with levels>0.01% by ﬂow cytometry for ALL and> 0.1% for
AML/MPAL, or detectable disease by cytogenetics.
* Log-rank P value for comparison of relapse-free survival (relapse versus no relapse).
y P value is in comparison of relapse-free survival for those with active disease to those in CR.
z High-risk determination was made by transplant physician using a constellation of multiple assessments, which included cytogenetics (eg, monosomy 7,
hypodiploid <43 chromosomes, FLT3/ITD), end-induction MRD positivity and/or phenotype (MPAL) and in conjunction with standard accepted criteria for
transplant indications.
x Two patients with refractory disease before HCT died from early TRM before dayþ100. One patient with refractory AML remains a long-term survivor post-
HCT without relapse.
k Many patients who received the initial haploidentical transplants were on an institutional nonmyeloablative protocol, which also included patients with
active disease at the time of HCT.
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patient who died from early TRM at day þ118 post-HCT with
rising levels of MRD at the time of death. All patients who
received disease-directed therapy died from TRM, with the
exception of 1 patient with MDS who presented with MRD
based on evidence of cytogenetic relapse at day þ180 post-
transplantation and received DLI before further disease
progression occurred. This patient remains a long-term sur-
vivor. Survival of patients who presented with MRD post-transplantation was no better than that in patients who
presented with frank relapse, despite preemptive in-
terventions for MRD.
DISCUSSION
Despite the hypothesis that treatment of post-HCT MRD
may represent a window of opportunity for relapse preven-
tion and thereby improve outcomes, our ﬁndings do not
support this as an optimal strategy for relapse prevention in
Table 2
Relapse Rate and Time to Relapse for Patients with ALL and AML in a Morphological Remission at HCT who Underwent a Myeloablative Preparative Regimen, by
Pre-HCT MRD Status
Disease Pre-HCT MRD
Status
Total
Patients
Number of Patients Experiencing Relapse at or before the Planned
Restaging Evaluation Time Points
Total
Relapses
Crude Relapse
Rate, %
Median Time
to Relapse, d
Day 30 Day 60 Day 90 Day 180 Day 365 Day 365þ
ALL Negative 20 1 0 1 2 1 2 7 35 182
Positive 11 0 3* 0 1 3 0 7 64 132
AML Negative 15 0 0 0 0 2 1 3 20 238
Positive 11 0 0 0 2 1 1 4 36 224
ALL indicates acute lymphoblastic leukemia; AML, acute myelogenous leukemia; HCT, hematopoietic stem cell transplantation; MRD, minimal residual disease.
MRD considered positive when <5% and 0.01% in ALL and 0.1% in AML.
* Two patients presented with post-HCT MRD.
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despite the frequent monitoring, the majority of patients
(78%) who experienced relapse had already progressed to
morphological relapse by the time of disease detection.
Moreover, in patients with disease detected in a state ofMRD,
disease progression was often rapid, detected early post-
transplantation or identiﬁed at a time when ongoing toxic-
ities compromised the efﬁcacy of therapeutic interventions.
With the ability to monitor for much lower levels of dis-
ease burden using techniques that greatly increase the
sensitivity of disease detection [11], post-transplantation
MRD monitoring was performed at frequent, accepted
standard intervals at our center. Considering this rigorous
and multimodal routine post-transplantation evaluation,
including complete data from all disease evaluation time
points with disease assessment by ﬂow cytometry (with ALL
MRD analysis performed at our central reference laboratory),
molecular, and chimerism studies, the ﬁnding that the vast
majority of patients still presented with morphological
relapse was unexpected. This was especially notable in the
patients with ALL and AML who were in a morphological
remission at the time of transplantation and received a
myeloablative transplant. In this subgroup, only 2 of 21
patients who relapsed presented with post-transplantation
MRD before morphological relapse.
A possible explanation for this ﬁnding may be related to
the timing of disease recurrence in relation to the timing ofFigure 1. Cumulative incidence of relapse and TRM analyzed at competing risks st
allogeneic HCT for acute leukemia or MDS.disease evaluation. In this study, the median time to relapse
was 4.8 months post-transplantation, between the 3-month
and 6-month scheduled evaluations. This suggests that
adding an evaluation between 3 and 6 months may aid
earlier detection of MRD before morphological relapse.
Similarly, in a recent study of post-HCT MRD in ALL, Zhao
et al. [26] they also noted that MRD was not detected before
hematologic relapse in the patients who relapsed between 3
and 6 months, suggesting the need for additional evaluation
during this period. At our center, we continue to perform
frequent MRD surveillance, and often add an additional MRD
evaluation between the 3- and 6-month evaluations and
another at around 9 months post-transplantation for pa-
tients with high-risk disease.
The sensitivity of disease detection methods may be an
important consideration as well. Balduzzi et al. [21], in a
recent study evaluating pre- and post-HCT MRD in patients
with ALL using real-time quantitative polymerase chain
reaction methods, demonstrated that intervention for low-
level post-transplantation MRD (<1  104) can prevent
overt relapse. However, in their study, all those with higher-
level MRD (1  103) and those who experienced a 1-log
increase in MRD (albeit still at low levels), all ultimately
experienced overt relapse despite preemptive interventions.
In our cohort, 4 patients with AML relapse had higher-level
MRD, and those with ALL progressed rapidly. This suggests
the need for a more sensitive method of disease detection inarting at the date of HCT for 93 consecutive patients who underwent a ﬁrst
Figure 2. Median time to relapse, by relapse presentation. Routine marrow
evaluation was performed for all pediatric patients at approximately
days þ30, þ60, þ90, and þ180 and years þ1 and þ2 post-HCT. Analysis of
variance was used to analyze the differences in the time to relapse by the
various presentations of post-HCT relapse. The middle line in the boxplot in-
dicates the median, with whiskers indicating top and bottom quarter per-
centiles (P < .001).
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nostic implications of very low levels of disease; however,
this strategy might not be useful for predicting extra-
medullary relapse, whichmight not be reliably detectedwith
bone marrow monitoring [21,26,30]. Six patients in our
cohort presented with extramedullary relapse as the ﬁrst
manifestation of disease recurrence without previous
marrow disease involvement.
Even with more frequent monitoring and more sensitive
measures of disease detection, whether these measures would
improve outcomes for the majority of patients with post-
transplantation relapse is uncertain, given the ability to treat
onlyvery lowlevelsofdiseaseandthepotential for rapiddisease
progression. In our study, the median time of disease progres-
sion from the detection of post-transplantation MRD to overt
relapse was relatively short (median, 21 days), with other
studies reporting times to overt relapse of 1 to 3 months after
detection of MRD [26]. Immunotherapeutic approaches to
induce a graft-versus-leukemia effect with early withdrawal of
immunosuppressionorDLImaybebeneﬁcial andmosteffective
in patients with early relapse and low disease burden, but may
require weeks to take effect and have limited efﬁcacy in the
setting of rapid disease progression or higher disease burden
[21,31,32]. Moreover, this might not be an option in those with
pre-existing GVHD [13,33-37]. Disappointingly, in our study,
similar to other reports [5,21,32,38], the use of DLI, even pre-
emptively, was not associated with long-term survival in pa-
tients with acute leukemia. Other treatment options for MRD,
especially in the early post-transplantation setting, are limited
by ongoing transplantation-related comorbidities. Cytoreduc-
tive therapy is generally poorly tolerated; accordingly, all of our
patients who received chemotherapy to treat post-
transplantation MRD died from treatment-related toxicity.In light of the limited ability to treat post-transplantation
MRD, our study provides further support for the need to
improve pretransplantation risk stratiﬁcation for identifying
those patients at greatest risk for relapse in whom early in-
terventions for relapse prevention, such as early withdrawal
of immunosuppression or DLI, would be indicated [21,25,39].
Given the important prognostic value of pretransplantation
MRD status on post-transplantatin outcomes, speciﬁcally in
patients with ALL [40], pretransplantation MRD reduction is
another strategy that may lead to improved post-
transplantation outcomes [21]. Because this patient popula-
tion has relatively chemotherapy-refractory disease, we now
consider referring patients with pretransplantation MRD for
novel immunotherapeutic clinical trials for MRD reduction
(eg, chimeric antigen receptor therapy, immunotoxin ther-
apy) before HCT in an attempt to improve post-transplant
outcomes, an approach that requires further evaluation.
Although pretransplantation MRD positivity is the most
strongly predictive factor of post-transplantation relapse
[40-42], we do not believe that this factor should preclude
proceeding to HCT. Certainly, improved preemptive in-
terventions may reduce the risk of relapse in those with
pretransplantation MRD. In our cohort, among the patients
who received myeloablative conditioning and were in a
morphological remission, 10 of 35 patients (28.5%) whowere
MRD negative and 11 of 22 patients (50%) who were MRD
positive experienced relapse (Table 2). Consistent with other
studies [28], patients with pretransplantation MRD had a
higher rate of relapse, but many were able to experience
disease-free survival, with a lower prognostic value of pre-
transplantation MRD in patients with AML compared with
those with ALL.
Themain limitation of our study is its retrospective design
incorporating a heterogeneous patient population, including
higher-risk patientswith refractory disease and/or thosewho
received nonmyeloablative/reduced-intensity pretransplan-
tation conditioning. Similar ﬁndings were seen in patients
who were in remission and received myeloablative condi-
tioning, however. In addition, the limited sensitivity of our
AML ﬂow cytometry MRDmight have missed very low levels
ofMRDbefore overt relapse, biasingmore of the patientswith
AML to present at a state of higher disease burden, when
intervention was less effective. Certainly, ongoing develop-
ment focused on optimizing evaluation of AML MRD should
be implemented to improve the ability of disease detection to
attempt early preemptive intervention for relapse prevention
[42-44].
In conclusion, our results illustrate the challenges in
treating post-transplantation MRD for relapse prevention
in patients with acute leukemia. The primary challenge
lies in the fact that most patients who relapse may already
be in a state of overt relapse at the time of disease detection.
Our results do not indicate a survival advantage for those
with relapse detected at the stage of MRD. Whether more
frequent or more sensitive measures of disease evaluation
in the early post-transplantation period to potentially
identify an even lower degree of MRD or detect disease
before overt relapse would lead to improved out-
comes merits further exploration. Nonetheless, post-
transplantation intervention may still be limited by the
early timing of relapse and/or rapid disease progression.
Given the poor outcomes once post-transplantation disease
is detected, improved pretransplantation risk stratiﬁcation
and a shift of focus to relapse prevention are needed to
improve post-transplantation outcomes.
Table 3
Outcomes of Patients with Leukemia and Post-HCT MRD
Patient Disease Pre-HCT Disease
Status
Conditioning Donor Days fromHCT to
Detection of
Post-HCT MRD
% MRD* Mode of Detection Days from HCT to
Overt Relapse
Days from HCT to
First Intervention
Intervention Survival
after
HCT, d
Cause of Death Disease
Status at
Last
Evaluation
2 ALL þBCR-ABL 0.01%
by RT-PCR only,
ﬂow negative
MA (Cy/TBI) MSD 60 0.01 Flow cytometry
and
cytogenetics, þ
BCR-ABL PCR
84 90 Chemo 115 Multiorgan failure PD
6 ALL 0.29% MRD by
ﬂow
MA (Cy/TBI) MSD 56 0.01 Flow cytometry NA 70 DLI 83 CMV pneumonia,
ARDS
None
performed
before
death
76 ALL þBCR-ABL 0.03%
by RT-PCR only,
ﬂow negative
NMA Haploidentical 35 BCR-ABL
detection by RT-
PCR, non-
quantiﬁable
Cytogenetics Increasing copies
of BCR-ABL
without overt
relapse
No treatment
initiated due to
ongoing toxicities
post-HCT
NA 153 Adenovirus,
pulmonary
hemorrhage, fungal
infection
CR
46 AML MRD-negative CR NMA Haploidentical 30 0.08 Cytogenetics 51 30y WIS/2nd
HCT
247 Multiorgan failure,
GVHD, sepsis
CR
49 AML 1% by ﬂow NMA Haploidentical 29 3 Flow cytometry 50 52 Chemo þ
DLI
81 Sepsis PD
63 AML Refractory
disease
MA (Bu/Cy) MUD 64 1 Flow cytometry 77 69y WIS/
Chemo
138 Sepsis PD
65 AML Refractory
disease, CNS
negative
MA (Bu/Cy) MUD 28 2-3 Flow cytometry 45 29y WIS/
Chemo
150 VOD, GVHD PD
HCT indicates hematopoietic stem cell transplantation; MRD, minimal residual disease; ALL, acute lymphoblastic leukemia; BCR-ABL, tyrosine kinase gene; RT-PCR, reverse-transcriptase polymerase chain reaction; MA,
myeloablative; Cy, cyclophosphamide; TBI, total body irradiation; MSD, matched sibling donor; CMV, cytomegalovirus; ARDS, acute respiratory distress syndrome; NMA, nonmyeloblative; AML, acute myelogenous leukemia;
WIS, withdrawal of immunosuppression; GVHD, graft-versus-host disease; PD, progressive disease; Bu, busulfan; DLI, donor lymphocyte infusion; Chemo, chemotherapy; VOD, veno-occlusive disease; MUD, matched unrelated
donor; CNS, central nervous system.
* Indicates the level of disease detected at the ﬁrst evidenceof MRD; speciﬁcally, for those patients who presented at days 56, 60, and 64, previous disease restaging at 1 month post-HCT was negative.
y Indicates that therapy was initiated before overt relapse.
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